Noninvasive Markers of Portal Hypertension Detect Decompensation in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease

被引:18
|
作者
Mendoza, Yuly [1 ]
Cocciolillo, Sila [2 ]
Chen, Tianyan [1 ]
Margini, Cristina [2 ]
Sebastiani, Giada [1 ]
Berzigotti, Annalisa [2 ]
Murgia, Giuseppe [1 ]
机构
[1] Univ Bern, Bern Univ Hosp, Inselspital, Univ Clin Visceral Surg & Med,Dept Biomed Res, Bern, Switzerland
[2] McGill Univ, Royal Victoria Hosp, Div Gastroenterol & Hepatol, Hlth Ctr, Montreal, PQ, Canada
关键词
Cirrhosis; Ultrasound; NASH; Fibrosis; CONTROLLED ATTENUATION PARAMETER; STIFFNESS MEASUREMENT; RISK; COMPLICATIONS; PREDICTION; FIBROSIS;
D O I
10.1016/j.cgh.2020.04.018
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Some patients with compensated advanced chronic liver disease (cACLD) require use of an extralarge probe for liver stiffness measurement (LSM), owing to overweight or obesity. However, the ability of noninvasive markers of portal hypertension and the controlled attenuation parameter (CAP) to determine which of these patients are at risk for decompensation has not been fully assessed. METHODS: We collected data from 272 patients with cACLD (LSM double dagger 10 kPa by XL probe; 57% with nonalcoholic steatohepatitis; mean body mass index, 33.8 6.5 kg/m2; median Child-Pugh score, 5; median LSM, 16.8 kPa; mean CAP, 318 66 dB/m) evaluated at 2 academic centers from 2015 through 2018. We collected clinical data on decompensation (ascites, portal hypertension bleeding, jaundice, hepatic encephalopathy) and severe bacterial infections; patients were followed up for a median of 17 months (interquartile range, 11-24 mo). We evaluated associations between these events and LSM, CAP, LSM*spleen size/platelet count (LSPS), and portal hypertension risk scores. RESULTS: Decompensation occurred in 12 patients and severe bacterial infections developed in 5 patients. LSM, LSPS, and the portal hypertension risk score identified patients with decompensation with area under the receiver operating characteristic curve values of 0.848 (95% CI, 0.720-0.976; P < .0001), 0.881 (95% CI, 0.798-0.954; P < .0001), and 0.890 (95% CI, 0.814-0.966; P < .0001), respectively. In multivariate Cox regression analysis, in patients with nonalcoholic steatohepatitis, LSM and CAP were associated independently with decompensation and severe bacterial infection; CAP >= 220 dB/m was associated with a reduced risk of decompensation (hazard ratio, 0.043, 95% CI, 0.004-0.476; P =.01). CONCLUSIONS: LSM, LSPS, and the portal hypertension risk score identify obese or overweight patients with cACLD who are at increased risk of decompensation and severe bacterial infection.
引用
收藏
页码:3017 / +
页数:15
相关论文
共 50 条
  • [31] Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis
    Ferlitsch, Monika
    Reiberger, Thomas
    Hoke, Matthias
    Salzl, Petra
    Schwengerer, Bernadette
    Ulbrich, Gregor
    Payer, Berit Anna
    Trauner, Michael
    Peck-Radosavljevic, Markus
    Ferlitsch, Arnulf
    HEPATOLOGY, 2012, 56 (04) : 1439 - 1447
  • [32] Simple blood tests to diagnose compensated advanced chronic liver disease and stratify risk of clinically significant portal hypertension
    Semmler, Georg
    Hartl, Lukas
    Mendoza, Yuly Paulin
    Simbrunner, Benedikt
    Jachs, Mathias
    Balcar, Lorenz
    Schwarz, Michael
    Hofer, Benedikt Silvester
    Fritz, Laurenz
    Schedlbauer, Anna
    Stopfer, Katharina
    Neumayer, Daniela
    Maurer, Jurij
    Szymanski, Robin
    Meyer, Elias Laurin
    Scheiner, Bernhard
    Quehenberger, Peter
    Trauner, Michael
    Aigner, Elmar
    Berzigotti, Annalisa
    Reiberger, Thomas
    Mandorfer, Mattias
    HEPATOLOGY, 2024, 80 (04) : 791 - 806
  • [33] CLINICAL OUTCOMES IN PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) TREATED WITH NON SELECTIVE BETA BLOCKERS
    Guthrie, Sarah
    Patanwala, Imran
    GUT, 2023, 72 (SUPPL_3) : A61 - A62
  • [34] CLINICAL OUTCOMES IN PATIENTS WITH CLINICALLY SIGNIFICANT PORTAL HYPERTENSION AND COMPENSATED ADVANCED CHRONIC LIVER DISEASE (CACLD) TREATED WITH NON SELECTIVE BETA BLOCKERS
    Guthrie, Sarah
    Patanwala, Imran
    GUT, 2023, 72 : A61 - A62
  • [35] Validation of noninvasive methods to predict the presence of gastroesophageal varices in a cohort of patients with compensated advanced chronic liver disease
    Llop, Elba
    Lopez, Marta
    de la Revilla, Juan
    Fernandez, Natalia
    Trapero, Maria
    Hernandez, Marta
    Fernandez-Carrillo, Carlos
    Pons, Fernando
    Luis Martinez, Jose
    Luis Calleja, Jose
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 (11) : 1867 - 1872
  • [36] CHESS-ALARM score to stratify decompensation risk in compensated advanced chronic liver disease patients: An international multicenter study
    Wong, Yu Jun
    Li, Jia
    Liu, Chuan
    Chen, Zhaojin
    Chan, Yiong Huak
    Putera, Martin
    Teh, Kok Ban
    Ang, Tiing Leong
    Zhao, Lili
    Yan, Zhongfang
    Kumar, Rahul
    Li, Xin
    Qi, Xiaolong
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 (06) : 1043 - 1051
  • [37] METABOLOMICS IMPROVES THE PREDICTION OF RISK OF DECOMPENSATION OR LIVER RELATED DEATH IN PATIENTS WITH COMPENSATED CIRRHOSIS AND CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
    Maria Nicoara-Farcau, Oana
    Jose Lozano, Juan
    Sidorova, Julia
    Villanueva Sanchez, Candido
    Albillos, Agustin
    Genesca, Joan
    Luis Calleja, Jose
    Aracil, Carles
    Banares, Rafael
    Maria Morillas, Rosa
    Poca Sans, Maria
    Penas, Beatriz
    Augustin, Salvador
    Perez-Campuzano, Valeria
    Hernandez-Gea, Virginia
    Abraldes, Juan G.
    Alvarado Tapias, Edilmar
    Torres, Ferran
    Bosch, Jaime
    Carlos Garcia-Pagan, Juan
    HEPATOLOGY, 2022, 76 : S155 - S156
  • [38] Sequential shear-wave elastography of liver and spleen rules out clinically significant portal hypertension in compensated advanced chronic liver disease
    Jansen, Christian
    Bogs, Christopher
    Krag, Aleksander
    Francque, Sven
    Trebicka, Jonel
    GUT, 2017, 66 (03) : 558 - 559
  • [39] Prevention of First Decompensation in Advanced Chronic Liver Disease
    Mandorfer, Mattias
    Simbrunner, Benedikt
    CLINICS IN LIVER DISEASE, 2021, 25 (02) : 291 - 310
  • [40] CLINICALLY SIGNIFICANT PORTAL HYPERTENSION BY NON-INVASIVE TESTS IN COMPENSATED ADVANCED CHRONIC LIVER DISEASE DUE TO METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) WITH OBESITY AND OVERWEIGHT
    Vezozzo, Denise
    Reinoso, Gleicy
    Rocha, Betania
    Ziteli, Patricia
    Rocha, Sofia
    Stefano, Jose Tadeu
    Franca, Joao Italo Dias
    Carrilho, Flair Jose
    Oliveira, Claudia
    HEPATOLOGY, 2024, 80 : S638 - S638